TLX
Telix Pharmaceuticals Limited
NASDAQ: TLX · HEALTHCARE · BIOTECHNOLOGY
$10.10
-0.88% today
Updated 2026-07-29
Market cap
$3.56B
P/E ratio
—
P/S ratio
4.43x
EPS (TTM)
$-0.02
Dividend yield
—
52W range
$6 – $15
Volume
0.2M
Telix Pharmaceuticals Limited (TLX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$10.10
12-Month target
$0.14
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.2B | $0.5B | $0.8B | $1.2B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -0.89%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.